newsfilter
← Latest News
GlobeNewswire·

Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses

  • The U.S. FDA has cleared Oculis' Investigational New Drug (IND) application for Privosegtor to treat acute multiple sclerosis (MS) relapses.
  • This clearance enables Oculis to expand its clinical development program from optic neuritis to acute MS relapses by building upon positive Phase 2 ACUITY trial results & the ongoing PIONEER program.
  • The proposed clinical strategy includes patients with MS who experience optic neuritis or ambulatory relapses, utilizing a primary endpoint at three months & a 3mg/kg daily dose for five days.
  • Privosegtor is positioned as a potential first neuroprotective therapy to preserve nerve integrity during acute MS relapses, addressing an unmet need since current standard-of-care therapies only reduce inflammation or relapse frequency.
  • Oculis will host an R&D Day on December 8, 2026, to provide further updates on the Privosegtor development program for acute MS relapses & the PIONEER program in optic neuropathies.
  • Privosegtor previously demonstrated neuroprotective effects in the ACUITY trial by improving visual function, preserving retinal ganglion cell layers, & reducing biomarkers of axonal injury & astrocytic activation.
Company
Oculis Holding AG
Keywords
Nasdaq:OCS, Oculis Holding AG, Neuro-Ophthalmology, Neurology, Multiple Sclerosis